O’Melveny Represents INT Medical in US$113 Million New H-Share Placement
January 22, 2026
FOR IMMEDIATE RELEASE
HONG KONG—January 22, 2026—O’Melveny represented Shanghai INT Medical Instruments Co., Ltd. (“INT Medical”, 1501.HK) in its placing of 35,200,000 new H shares under general mandate, at HK$26.00 per placing share. The placement generated net proceeds of approximately HK$884.31 million (approximately US$113 million). CICC and Industrial Securities International acted as the joint placing agents.
The placement was announced on January 14, 2026, and completed on January 22, 2025. INT Medical intends to use the proceeds primarily to support its business development, including potential investments and acquisitions in the medical devices sector.
INT Medical is a leading Chinese manufacturer of vascular interventional devices, and one of the few medical device groups in China with a fully integrated supply chain.
The O’Melveny team was led by partners Ke Geng and Ke Zhu. The core team members included senior legal manager Alfred Li, and legal consultant Audrey Zhan.
About O’Melveny
It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at www.omm.com; learn more in our firm at-a-glance; and find us on LinkedIn, Facebook, Instagram, and YouTube.
Contact:
Brandon Jacobsen
O’Melveny & Myers LLP
+1 213 430 8024
bjacobsen@omm.com
Chris Schob
O’Melveny & Myers LLP
+86 21 2307 7000
cschob@omm.com
# # #